Med. praxi. 2017;14(1):21-24 | DOI: 10.36290/med.2017.005

Volunary vaccination in the general practitioner΄s office

MUDr. Zarina Karimová, MUDr. Vendula Petrůjová, MUDr. Hana Roháčová, Ph.D.
Klinika infekčních, parazitárních a tropických nemocí, Nemocnice na Bulovce, Praha

In spite of the existing series of myths and unreasonable fear of vaccination, it still endures as one of the most effective

and safe tool in preventing different infectious diseases, which remain the significant cause of morbidity and mortality all

over the globe in all possible age groups. Infectious diseases are held responsible for over one third of deceases worldwide

and for almost half of the deceases in the developing countries. Vaccination is a reliable prevention tool in any age and

therefore should not be a subject of interest only for pediatricians. Priority for general practitioners must be vaccination of

patients in so called “risk group” (elderly, polymorbid patients, immunocompromised patients) and vaccination of parents

with small children.

Keywords: vaccination, immunization, vaccines’ application, vaccines’ features, pneumococcal infections, influenza virus, human papillomavirus (HPV)

Published: March 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karimová Z, Petrůjová V, Roháčová H. Volunary vaccination in the general practitioner΄s office. Med. praxi. 2017;14(1):21-24. doi: 10.36290/med.2017.005.
Download citation

References

  1. World Health Organization data. Immunization, Vaccines and Biologicals.
  2. The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective [online]. 2014-06-11. Dostupné na www: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143534.htm
  3. EudraLex - Volume 4 Good manufacturing practice (GMP) Guidelines [online]. Dostupné na www: http://ec.europa.eu/health/documents/eudralex/vol-4/
  4. Mitkus RJ, et al. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine 29 (2011): 9538-9543. Go to original source... Go to PubMed...
  5. Andrews N, Miller E. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a casual association. Pediatrics. 2004; 114: 584-591. Go to original source... Go to PubMed...
  6. Heron J, Golding J. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a casual association. Pediatrics. 2004; 114: 577-583. Go to original source... Go to PubMed...
  7. Bartůňková J, Šedivá A. Imunologie - minimum pro praxi. Praha: Triton 2001.
  8. Předpis 225/2005 Sb. [online]. Dostupné z www: https://www.psp.cz/sqw/sbirka.sqw?cz=225&r=2005
  9. Petráš M, Domorázková E, Petrýdesová A. Manuál očkování II. Tango s.r.o. Praha 1998.
  10. Whitney CG, Shaffner W, Buttler JC. Rethinking recommendations for use of pneumococcal vaccines in adults. Clin Infect Dis, 2001, 33. Go to original source... Go to PubMed...
  11. Stránky České vakcinologické společnosti: www.vakcinace.eu
  12. FUTURE II Study Group: Quadrivalent vaccine against HPV to prevent high-grade cervical lesions. N Engl J Med. 2007; 356(19): 1915-1927. Go to original source... Go to PubMed...
  13. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against HPV to prevent anogenital disease (FUTURE I). N Engl J Med. 2007; 356(19): 1928-1943. Go to original source... Go to PubMed...
  14. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1649-1651. Go to original source... Go to PubMed...
  15. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from randomised control trial. Lancet 2006; 367: 1247-1255. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.